HOME >> BIOLOGY >> NEWS
Stem cell specialists face questioning

A top panel of experts will face questions of public and scientific concern on stem cell research during an international conference being held at The University of Manchester this week.

The Stem Cell Question Time will be headed by Lord Naren Patel, chair of the UK National Stem Cell Network, as part of Stem Cell Manchester, a three-day gathering of stem cell researchers from across the globe.

Among the panellists at Wednesdays event will be Ron McKay from the National Institutes of Health, Bethesda, USA, Justine Burley, from the University of Singapore, and Jed Davies, from the University of Toronto, Canada.

The audience, which will be comprised of scientists both within and outside the field, will be invited to submit questions on important, contentious and challenging issues facing the stem cell research community.

Such topics up for discussion are likely to focus on the ethical issues surrounding stem cell research as well as the scientific challenges that must be overcome if this cutting-edge branch of biomedical research is to fulfil its true potential.

Also on the panel are Alan Coleman, from Embryonic Stem Cell International, Singapore, Chris Mason, from University College, London, and Daniel Brison, Co-director of the Northwest Embryonic Stem Cell Research Centre based at St Marys Hospital and The University of Manchester.

The Stem Cell Manchester conference has attracted leading figures in stem cell research from across the world, said organiser Professor Tim Hardingham, who is based in Manchesters Faculty of Life Sciences.

We have a packed programme of speakers lined up over the next few days culminating with the Question Time event on Wednesday where people outside the field can take part in a full and frank debate of the issues surrounding stem cell research.

Among the speakers at the conference is Shinya Yamanaka, whose team at Kyoto University in Japan is pioneering wa
'"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
16-Jul-2007


Page: 1 2

Related biology news :

1. Heart specialists call for cardiovascular screening for all young competitive athletes
2. Bone specialists hi-tech answer to patient care
3. NNii media advisory about David Kirbys book questioning vaccine safety

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Stem cell specialists face questioning

(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
(Date:12/19/2014)... (PRWEB) December 18, 2014 LayerBio is ... ophthalmology and wound care. The National Eye Institute (NEI) ... LayerBio a Phase I SBIR grant to develop a ... are the most common cause of vision loss in ... blindness worldwide. According to Dr. Ken Mandell, LayerBio’s Founder ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... Dec. 18, 2014 Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced the results of its ... "This was a transformational year in Relmada,s history and ... our company," said Sergio Traversa , chief executive ... executed on key financial, human resource and clinical development ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: